HKU Scholars Hub: Browsing DSpace

Browsing by Author Agarwal, K

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中

or enter first few letters:

Showing results 38 to 41 of 41 < previous

	Title	Author(s)	Issue Date
	Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial Journal:The Lancet Gastroenterology & Hepatology	Chan, HL Fung, S Seto, WKW Chuang, WL Chen, CY Kim, HJ Hui, AJ Janssen, H Chowdhury, A Tsang, TY Rajiv, M Gane, E Flaherty, J Massetto, B Gaggar, A Kitrinos, KM Lin, L Subramanian, GM McHutchison, J Lim, YS Acharya, SK Agarwal, K	2016
	The Capsid Assembly Modulator ALG-000184 dosed for 28 days was well tolerated and rapidly reduced viral markers in subjects with chronic hepatitis B, including HBsAg in a subset of HBeAg positive subjects with elevated baseline ALT Proceeding/Conference:Hepatology International	Gane, E Yuen, MF Agarwal, K Juov, A Hou, J Niu, J Massetto, B Le, K Lin, TI McClure, M	31-Mar-2023
	The second-generation hepatitis B virus (HBV) core inhibitor (CI) ABI-H2158 is associated with potent antiviral activity in a 14-day monotherapy study in HBeAg-positive patients with chronic hepatitis B (CHB) Proceeding/Conference:Hepatology	Yuen, RMF Agarwal, K Gane, EJ Nguyen, TT Hassanein, T Kim, DJ Alves, K Zayed, H Qiang, DM Ruby, E Evanchik, M Huang, Q Knox, S Colonno, R on behalf of ABI-H2158 Study Team	2019
	Three Year Efficacy and Safety of Tenofovir Alafenamide (TAF) Compared to Tenofovir Disoproxil Fumarate (TDF) in Hbeag-Negative and Hbeag-Positive Patients with Chronic Hepatitis B Proceeding/Conference:Hepatology	Chan, HLY Lim, YS Seto, WKW Agarwal, K Brunetto, MR Janssen, HLA Caruntu, F Stepanova, T Tsang, O Yatsuhashi, H Tak, WY Chen, CY Celen, M Sun, V Flaherty, JF Lin, L Cathcart, A Gaggar, A Pan, CQ Shalimar Buti, M	2018

Showing results 38 to 41 of 41 < previous